KA/EN
Register
Medicines reference
Search
Search
Active substance

Sarolaner

Favourites

Isoxazoline ectoparasiticide. Registered in Georgia: 15 veterinary products. Forms: chewable tablet, spot-on.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Sarolaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
2–4 mg/kg Dog Maintenance By mouth monthly
VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Simparica 5 mg chewable tablets for dogs 1.3-2.5 kg - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. Pregnancy and lactation: The use in these animals is not recommended. Fertility: The use in breeding animals is not recommended. The safe use of SIMPARICA has not been evaluated in breeding, pregnant, or lactating dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning (Dog)
    Pregnancy and lactation: The use in these animals is not recommended.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. less than 1.25 kg
    Sources: VMD SPC · VMD
  • Warning (Dog)
    The minimum age for sarolaner depends on the product label. Some labels permit use from 8 weeks, while the US Simparica label restricts use to dogs at least 6 months old because younger puppies developed neurological signs at high multiples of the dose. Follow the selected product’s label.
    Sources: VMD SPC · VMD · FDA
  • Caution (Dog)
    Sarolaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. mild tremors convulsions
    Sources: VMD SPC · VMD · FDA
Latin name
Sarolaner
Georgian name
საროლანერი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
15 of 15 forms
Products
Simparica, Simparica Trio, Stronghold Plus
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration15

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Simparica 5 mg, Chewable tablet

sarolaner 5 mg, chewable tablet for dogs 1.3-2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

5 mg, sarolaner 5 mg, chewable tablet for dogs 1.3-2.5 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 165-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 5მგ საღეჭი ტაბლეტი 1,3-2,5კგ ძაღლებისთვის
№ 165-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica 10 mg, Chewable tablet

sarolaner 10 mg, chewable tablet for dogs 2.5-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

10 mg, sarolaner 10 mg, chewable tablet for dogs 2.5-5 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 164-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner10 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 10მგ საღეჭი ტაბლეტი 2.5-5კგ ძაღლებისთვის
№ 164-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica 20 mg, Chewable tablet

sarolaner 20 mg, chewable tablet for dogs 5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

20 mg, sarolaner 20 mg, chewable tablet for dogs 5-10 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 157-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner20 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 20მგ საღეჭი ტაბლეტის 5-10კგ ძაღლებისთვის
№ 157-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica 40 mg, Chewable tablet

sarolaner 40 mg, chewable tablet for dogs 10-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

40 mg, sarolaner 40 mg, chewable tablet for dogs 10-20 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 163-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner40 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 450, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა -40მგ საღეჭი ტაბლეტი 10-20კგ ძაღლებისთვის
№ 163-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica 80 mg, Chewable tablet

sarolaner 80 mg, chewable tablet for dogs 20-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

80 mg, sarolaner 80 mg, chewable tablet for dogs 20-40 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 162-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner80 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 80მგ საღეჭი ტაბლეტი 20-40კგ ძაღლებისთვის
№ 162-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica 120 mg, Chewable tablet

sarolaner 120 mg, chewable tablet for dogs 40-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Simparica

120 mg, sarolaner 120 mg, chewable tablet for dogs 40-60 kg
Assessed clinical scopeDog · Full labelled canine scope for monthly treatment and control of susceptible fleas, ticks and mites · By mouth
Care settingMonthly weight-band chewable ectoparasite control after age, neurologic and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 156-11 · Verified on 15 Oct 2026

A strongly supported monthly canine ectoparasiticide with excellent efficacy and convenience; the main limitation is the class-wide neurological risk and jurisdiction-dependent age/breeding restrictions.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the product has mature current EU/UK and FDA authorisations with detailed public labels.

Clinical efficacy9.0/10

Randomized controlled laboratory and multicentre field studies show high and persistent monthly efficacy against labelled flea, tick and mite targets, with clinically useful speed of kill.

Safety and tolerability7.0/10

Safety is well characterised, but sarolaner is an isoxazoline and rare tremor, ataxia or seizures can occur even without prior history; pregnancy/breeding safety and young-puppy rules differ by jurisdiction.

Clinical practicality9.0/10

One palatable chew once monthly across six clear weight bands is highly practical; accurate weighing and use of the correct whole-tablet band remain essential.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazolines can be associated with tremor, ataxia and seizures, including in dogs without a prior seizure history; use particular caution with pre-existing neurologic disease.
  • Use only in dogs and only the correct whole-tablet weight band; do not split or extrapolate a strength to another species or band.
  • Age, pregnancy, lactation and breeding restrictions differ between current EU/UK and US labels; follow the locally applicable exact label and document the benefit-risk decision.
  • Confirm the parasite target and maintain the labelled monthly schedule; reassess breakthrough infestation, adherence and environmental reinfection rather than shortening intervals empirically.
Assessment sources
  1. VMD SPC 20242024
  2. FDA 20242024
  3. Simparica US flea field trial2016
  4. Simparica tick dose trials2016
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner120 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა - 120მგ საღეჭი ტაბლეტი 40-60კგ ძაღლებისთვის
№ 156-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-452
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica Trio 3 mg/0.06 mg/12.5 mg, Chewable tablet

sarolaner 3 mg + moxidectin 0.06 mg + pyrantel (as embonate) 12.5 mg, chewable tablet for dogs 1.25-2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

3 mg/0.06 mg/12.5 mg, sarolaner 3 mg + moxidectin 0.06 mg + pyrantel (as embonate) 12.5 mg, chewable tablet for dogs 1.25-2.5 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 182-11, 34-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner3 mg Moxidectin0.06 mg Pyrantel12.5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >1.25-2.5კგ
№ 182-11, 34-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica Trio 6 mg/0.12 mg/25 mg, Chewable tablet

sarolaner 6 mg + moxidectin 0.12 mg + pyrantel (as embonate) 25 mg, chewable tablet for dogs 2.5-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

6 mg/0.12 mg/25 mg, sarolaner 6 mg + moxidectin 0.12 mg + pyrantel (as embonate) 25 mg, chewable tablet for dogs 2.5-5 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 180-11, 404-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner6 mg Moxidectin0.12 mg Pyrantel25 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >2.5-5კგ
№ 180-11, 404-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica Trio 12 mg/0.24 mg/50 mg, Chewable tablet

sarolaner 12 mg + moxidectin 0.24 mg + pyrantel (as embonate) 50 mg, chewable tablet for dogs 5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

12 mg/0.24 mg/50 mg, sarolaner 12 mg + moxidectin 0.24 mg + pyrantel (as embonate) 50 mg, chewable tablet for dogs 5-10 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 185-11, 406-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner12 mg Moxidectin0.24 mg Pyrantel50 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >5-10კგ
№ 185-11, 406-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica Trio 24 mg/0.48 mg/100 mg, Chewable tablet

sarolaner 24 mg + moxidectin 0.48 mg + pyrantel (as embonate) 100 mg, chewable tablet for dogs 10-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

24 mg/0.48 mg/100 mg, sarolaner 24 mg + moxidectin 0.48 mg + pyrantel (as embonate) 100 mg, chewable tablet for dogs 10-20 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 184-11, 403-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner24 mg Moxidectin0.48 mg Pyrantel100 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >10-20კგ
№ 184-11, 403-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica Trio 48 mg/0.96 mg/200 mg, Chewable tablet

sarolaner 48 mg + moxidectin 0.96 mg + pyrantel (as embonate) 200 mg, chewable tablet for dogs 20-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

48 mg/0.96 mg/200 mg, sarolaner 48 mg + moxidectin 0.96 mg + pyrantel (as embonate) 200 mg, chewable tablet for dogs 20-40 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 179-11, 402-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner48 mg Moxidectin0.96 mg Pyrantel200 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >20-40კგ
№ 179-11, 402-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Simparica Trio 72 mg/1.44 mg/300 mg, Chewable tablet

sarolaner 72 mg + moxidectin 1.44 mg + pyrantel (as embonate) 300 mg, chewable tablet for dogs 40-60 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.2/10
Very good
vetman assessment

Simparica Trio

72 mg/1.44 mg/300 mg, sarolaner 72 mg + moxidectin 1.44 mg + pyrantel (as embonate) 300 mg, chewable tablet for dogs 40-60 kg
Assessed clinical scopeDog · Full labelled canine combined-parasite scope when ectoparasite treatment and one or more nematode, heartworm or lungworm indications are concurrently required · By mouth
Care settingMonthly weight-band chewable integrated parasite control after indication, heartworm, age, neurologic and MDR1-risk assessment
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 181-11, 33-11 · Verified on 15 Oct 2026

A highly effective, well-documented integrated monthly option when its combined indication is genuinely present; broader coverage brings more screening and safety obligations than sarolaner alone.

Regulatory and scientific credibility9.0/10

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Clinical efficacy9.0/10

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

Safety and tolerability6.5/10

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

Clinical practicality8.5/10

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Isoxazoline-associated tremor, ataxia and seizures can occur, including without prior history; use particular caution in dogs with neurologic disease.
  • In heartworm-endemic settings, test dogs according to the exact label before preventive use; heavily microfilaraemic dogs may develop hypersensitivity-type reactions after treatment.
  • Use only in dogs and only the correct whole-tablet weight band. Strictly observe the dose in MDR1-sensitive breeds and do not split tablets.
  • Use the combination only when ectoparasite treatment and one or more additional labelled nematode, heartworm or lungworm indications are concurrently required.
  • Pregnancy, lactation, breeding and very-young-puppy use require the locally applicable exact-label benefit-risk rules.
Assessment sources
  1. VMD SPC 20252025
  2. FDA 20252025
  3. Trio EU flea/tick field trials2020
  4. Trio heartworm trials2019
  5. Trio hookworm trials2020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sarolaner72 mg Moxidectin1.44 mg Pyrantel300 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სიმპარიკა ტრიო - საღეჭი ტაბლეტები ძაღლებისთვის >40-60კგ
№ 181-11, 33-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-521
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold Plus 15 mg/2.5 mg, Spot-on

selamectin 15 mg + sarolaner 2.5 mg, spot-on solution for cats up to 2.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Stronghold Plus

15 mg/2.5 mg, selamectin 15 mg + sarolaner 2.5 mg, spot-on solution for cats up to 2.5 kg
Assessed clinical scopeCat · Full labelled feline mixed-parasite scope when tick control and at least one other labelled target are required together: fleas, ticks, heartworm prevention, roundworms, hookworms, lice, ear mites and notoedric mange · On the skin
Care settingVeterinary-selected monthly or single-dose integrated parasite control based on the exact indication
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 130-11 · Verified on 15 Oct 2026

A strong monthly feline endectoparasite option when tick control and another labelled target coincide; avoid the extra sarolaner component when tick treatment is not needed.

Regulatory and scientific credibility9.0/10

All three exact strengths have current transparent official SPCs and active Georgian veterinary registration, supported by multiple indication-specific field and controlled trials.

Clinical efficacy8.5/10

Field and controlled studies support strong monthly flea and tick control and high efficacy for labelled mites and other selamectin-sensitive parasites; the fixed combination is justified only when tick control and another target are needed together.

Safety and tolerability7.0/10

Usually well tolerated, but do not use in cats with concurrent disease or in debilitated, underweight animals; reproduction lacks combination safety data and rare neurologic reactions are possible with the isoxazoline component.

Clinical practicality8.5/10

A single colour-coded weight-band pipette is simple and monthly scheduling is clear, but it must reach dry skin, licking must be prevented and single-dose versus monthly indications must not be confused.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in cats with concurrent disease or in debilitated and underweight cats, or in hypersensitivity to either active substance or an excipient.
  • Use the fixed combination only when tick control and at least one other labelled parasite target are indicated at the same time.
  • Use only from 8 weeks of age and at least 1.25 kg; apply the exact pipette to dry skin at the neck and never into the ear canal or by mouth.
  • Combination safety is not established in breeding, pregnant or lactating cats; use only after an individual benefit-risk assessment.
Assessment sources
  1. VMD SPC 20252025
  2. Stronghold Plus field studies2017
  3. Stronghold Plus notoedres RCT2025
  4. Stronghold Plus tick RCT2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin15 mg Sarolaner2.5 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდ პლუსი 15მგ/2.5მგ დასაწვეთებელი ხსნარი კატებისთვის ≤ 2.5კგ
№ 130-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-502
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold Plus 30 mg/5 mg, Spot-on

selamectin 30 mg + sarolaner 5 mg, spot-on solution for cats >2.5-5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Stronghold Plus

30 mg/5 mg, selamectin 30 mg + sarolaner 5 mg, spot-on solution for cats >2.5-5 kg
Assessed clinical scopeCat · Full labelled feline mixed-parasite scope when tick control and at least one other labelled target are required together: fleas, ticks, heartworm prevention, roundworms, hookworms, lice, ear mites and notoedric mange · On the skin
Care settingVeterinary-selected monthly or single-dose integrated parasite control based on the exact indication
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 128-11 · Verified on 15 Oct 2026

A strong monthly feline endectoparasite option when tick control and another labelled target coincide; avoid the extra sarolaner component when tick treatment is not needed.

Regulatory and scientific credibility9.0/10

All three exact strengths have current transparent official SPCs and active Georgian veterinary registration, supported by multiple indication-specific field and controlled trials.

Clinical efficacy8.5/10

Field and controlled studies support strong monthly flea and tick control and high efficacy for labelled mites and other selamectin-sensitive parasites; the fixed combination is justified only when tick control and another target are needed together.

Safety and tolerability7.0/10

Usually well tolerated, but do not use in cats with concurrent disease or in debilitated, underweight animals; reproduction lacks combination safety data and rare neurologic reactions are possible with the isoxazoline component.

Clinical practicality8.5/10

A single colour-coded weight-band pipette is simple and monthly scheduling is clear, but it must reach dry skin, licking must be prevented and single-dose versus monthly indications must not be confused.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in cats with concurrent disease or in debilitated and underweight cats, or in hypersensitivity to either active substance or an excipient.
  • Use the fixed combination only when tick control and at least one other labelled parasite target are indicated at the same time.
  • Use only from 8 weeks of age and at least 1.25 kg; apply the exact pipette to dry skin at the neck and never into the ear canal or by mouth.
  • Combination safety is not established in breeding, pregnant or lactating cats; use only after an individual benefit-risk assessment.
Assessment sources
  1. VMD SPC 20252025
  2. Stronghold Plus field studies2017
  3. Stronghold Plus notoedres RCT2025
  4. Stronghold Plus tick RCT2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin30 mg Sarolaner5 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდ პლუსი 30მგ/5მგ დასაწვეთებელი ხსნარი კატებისთვის > 2.5–5 კგ
№ 128-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-502
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Stronghold Plus 60 mg/10 mg, Spot-on

selamectin 60 mg + sarolaner 10 mg, spot-on solution for cats >5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Stronghold Plus

60 mg/10 mg, selamectin 60 mg + sarolaner 10 mg, spot-on solution for cats >5-10 kg
Assessed clinical scopeCat · Full labelled feline mixed-parasite scope when tick control and at least one other labelled target are required together: fleas, ticks, heartworm prevention, roundworms, hookworms, lice, ear mites and notoedric mange · On the skin
Care settingVeterinary-selected monthly or single-dose integrated parasite control based on the exact indication
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 127-11 · Verified on 15 Oct 2026

A strong monthly feline endectoparasite option when tick control and another labelled target coincide; avoid the extra sarolaner component when tick treatment is not needed.

Regulatory and scientific credibility9.0/10

All three exact strengths have current transparent official SPCs and active Georgian veterinary registration, supported by multiple indication-specific field and controlled trials.

Clinical efficacy8.5/10

Field and controlled studies support strong monthly flea and tick control and high efficacy for labelled mites and other selamectin-sensitive parasites; the fixed combination is justified only when tick control and another target are needed together.

Safety and tolerability7.0/10

Usually well tolerated, but do not use in cats with concurrent disease or in debilitated, underweight animals; reproduction lacks combination safety data and rare neurologic reactions are possible with the isoxazoline component.

Clinical practicality8.5/10

A single colour-coded weight-band pipette is simple and monthly scheduling is clear, but it must reach dry skin, licking must be prevented and single-dose versus monthly indications must not be confused.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in cats with concurrent disease or in debilitated and underweight cats, or in hypersensitivity to either active substance or an excipient.
  • Use the fixed combination only when tick control and at least one other labelled parasite target are indicated at the same time.
  • Use only from 8 weeks of age and at least 1.25 kg; apply the exact pipette to dry skin at the neck and never into the ear canal or by mouth.
  • Combination safety is not established in breeding, pregnant or lactating cats; use only after an individual benefit-risk assessment.
Assessment sources
  1. VMD SPC 20252025
  2. Stronghold Plus field studies2017
  3. Stronghold Plus notoedres RCT2025
  4. Stronghold Plus tick RCT2017
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Selamectin60 mg Sarolaner10 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
Zoetis · United States
Manufacturer (register)
Zoetis Inc., United States
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 834, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სტრონგჰოლდ პლუსი 60მგ/10მგ დასაწვეთებელი ხსნარი კატებისთვის > 5–10კგ
№ 127-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-502
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗